Date: 2015-08-05
Type of information: Nomination
Compound:
Company: Acucela (USA - MA)
Therapeutic area: Ophtalmological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On August 5, 2015, Acucela, a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, announced that it has hired Dr. Lukas Scheibler as Executive Vice President of Translational Medicine. Dr. Scheibler joins Acucela after a 13-year career in research and development, business development and clinical trial management at Novartis Dr. Scheibler worked since 2008 at Alcon, a division of Novartis . He most recently was a Vice President in charge of Alcon’s Ideation and Technology Evaluation Center, the company’s center of excellence in charge of identifying novel technologies that address unmet needs in ophthalmology. Before that, he served as Alcon’s Vice President and Global Head of Clinical Trial Management. At Acucela, Dr. Scheibler will manage the translation of pre-clinical research into clinical development. He will play a key role in the Company’s business development team, manage the Company’s new projects before proof of concept to provide key dimensions of study protocols and oversee the Company’s relationships with major academic sites and research institutions. The Acucela Board of Directors appointed Dr. Scheibler as Executive Vice President of Translational Medicine, effective Aug. 17, 2015, at its Aug. 4 meeting in Seattle.
Financial terms:
Latest news:
